北 京 万 泰 生 物 药 业 股 份 有 限 公 司 2025 年第一次临时股东会会议资料 股票简称：万泰生物 股票代码：603392 2025 年 10 月 1 北京万泰生物药业股份有限公司 2025年第一次临时股东会会议资料 北京万泰生物药业股份有限公司 2025年第一次临时股东会会议资料 北京万泰生物药业股份有限公司 会议资料目录 三、会议议案 议案 1：《关于变更部分回购股份用途并注销的议案》 2 一、股东会须知 二、会议议程 北京万泰生物药业股份有限公司 2025年第一次临时股东会会议资料 2025 年第一次临时股东会须知 为了维护全体股东的合法权益，确保股东会的正常秩序和议事效率，保证会 议的顺利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市 公司股东会规则》以及《北京万泰生物药业股份有限公司章程》《北京万泰生物 药业股份有限公司股东会议事规则》的相关规定，特制定 2025 年第一次临时股 东会会议须知： 一、为确认出席会议的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次会议的严肃性和正常秩序，切 ...

Core Viewpoint - The company plans to change the purpose of repurchased shares from employee stock ownership plans to cancellation and reduction of registered capital, which will slightly decrease the total share capital without significant financial impact [1] Summary by Relevant Sections - **Shareholder Meeting**: The company will hold its first extraordinary general meeting of 2025 on October 31, 2025, to discuss the proposal regarding the change in the use of repurchased shares [1] - **Share Repurchase Details**: The company intends to repurpose 729,970 shares that have been repurchased but not yet utilized, changing their use from "for employee stock ownership plans or equity incentives" to "for cancellation and reduction of registered capital" [1] - **Impact on Total Share Capital**: Following the cancellation, the total share capital will decrease from 1,265,122,774 shares to 1,264,392,804 shares, indicating a minor adjustment in the company's capital structure [1] - **Financial Implications**: The proposed changes are not expected to have a significant impact on the company's financials and do not harm shareholder interests [1]

Core Insights - The first domestic nine-valent HPV vaccine was administered in Shenzhen, marking China as the second country globally to independently supply high-cost HPV vaccines [1] Group 1: HPV Vaccine Overview - The nine-valent HPV vaccine is approved for women aged 9 to 45, targeting two peak infection age groups: under 25 and 40-44 [3] - The vaccine covers nine types of HPV, including seven high-risk types, and has a pricing structure of 520 yuan per dose, making it more accessible [3] - The vaccination schedule varies by age: two doses for girls aged 9-17 and three doses for women aged 18-45 [3] Group 2: Cervical Cancer Statistics - Cervical cancer is a significant health threat in China, with 151,000 new cases reported in 2022, the highest globally [2] - The incidence of cervical cancer has been rising since 2000, with a trend towards younger age groups, particularly among women under 25 [2] Group 3: Public Health Initiatives - There are initiatives to promote HPV vaccination among schoolgirls, particularly in Guangdong Province, where a free vaccination program is available for first-year middle school girls [4] - The health authorities are conducting public awareness campaigns to educate women about the benefits of vaccination and cervical cancer prevention [4] Group 4: Clinical Efficacy and Safety - Clinical studies indicate that the domestic nine-valent HPV vaccine provides 100% protection against persistent infection from high-risk HPV types [4] - Most observed adverse events are mild to moderate and typically resolve on their own, similar to common reactions from other vaccines [4][5] Group 5: Research and Development - The vaccine was developed by a team from Xiamen University and Wantai Biological Pharmacy, utilizing a novel technology platform that has established a complete system of independent intellectual property rights [5]

Core Viewpoint - The first domestic nine-valent HPV vaccine in China has been administered in Shenzhen, marking a significant step in the country's ability to independently supply high-quality HPV vaccines, making China the second country globally to achieve this milestone [1][6]. Group 1: HPV Vaccine Introduction - The nine-valent HPV vaccine is approved for women aged 9 to 45, targeting two peak infection age groups: under 25 and 40-44 [6]. - The vaccine covers nine types of HPV, including seven high-risk types, and offers a reduced dosage schedule for younger girls, requiring only two doses for those aged 9-17, while women aged 18-45 need three doses [6]. - The price of the vaccine is set at 520 yuan per dose, making it more accessible and affordable for the public [6]. Group 2: Cervical Cancer Statistics and Prevention - Cervical cancer poses a significant health threat to women in China, with 151,000 new cases reported in 2022, the highest globally [5]. - The incidence of cervical cancer in China has been rising since 2000, with a trend towards younger age groups, particularly among women under 25 [5]. - HPV is responsible for 99.7% of cervical cancer cases, and vaccination is recognized as one of the safest and most effective preventive measures [5]. Group 3: Vaccine Development and Technology - The nine-valent HPV vaccine was developed by a team led by Academician Xia Ning Shao from Xiamen University in collaboration with Wantai Biological Pharmacy [7]. - The vaccine utilizes a globally innovative E. coli virus-like particle expression technology platform, overcoming long-standing technical barriers and establishing a complete system of independent intellectual property rights [7]. Group 4: Expert Recommendations - Experts emphasize the importance of vaccination to prevent persistent HPV infections, which are a significant risk factor for cervical cancer [7]. - It is recommended that eligible women, especially girls aged 9-14, should receive the HPV vaccine to protect themselves effectively [6][7].

Core Viewpoint - The company aims to build a comprehensive R&D system by benchmarking against world-class vaccine enterprises through a diversified model of "independent research + external cooperation + technology introduction" [1] Group 1 - The company is actively promoting international market expansion [1] - The company is enriching its product pipeline and diversifying its business layout [1] - The company is enhancing brand value and facilitating global cooperation [1] Group 2 - The company seeks to improve international brand influence through coordinated efforts across the entire industry chain [1]

Core Insights - The company has successfully sold its bivalent HPV vaccine in multiple overseas markets including Angola, Pakistan, Belarus, Cuba, Madagascar, Nicaragua, Nepal, El Salvador, Thailand, Tunisia, and Guatemala [1] Summary by Categories - **Product Development** - The bivalent HPV vaccine has achieved sales in various international markets, indicating successful product penetration and acceptance [1] - **Market Expansion** - The company has expanded its market reach to 11 countries, showcasing its international growth strategy and potential for further expansion [1]

Group 1 - The company has successfully sold its bivalent HPV vaccine in several countries, including Angola, Pakistan, Belarus, Cuba, Madagascar, Nicaragua, Nepal, El Salvador, Thailand, Tunisia, and Guatemala [1]

Core Viewpoint - The article discusses the significant reduction in the price of HPV vaccines in China, highlighting the transition from high costs to more accessible options, and the inclusion of HPV vaccines in the national immunization program, which marks a major step towards public health improvement [6][33]. Group 1: HPV Vaccine Market Dynamics - In 2022, China reported 156,000 new cervical cancer cases, with nearly 60,000 deaths, accounting for about 20% of global totals [6]. - The HPV vaccine, particularly the nine-valent version, has been in high demand despite its high price, which was around 6,300 yuan for a three-dose package in 2021 [9][11]. - The vaccination rate for girls aged 9-14 in China was only 4% in 2022, significantly lower than the global average of 61.6% [11]. Group 2: Price Reduction and Accessibility - The introduction of free HPV vaccinations in certain regions, such as the Ordos region, has led to a dramatic increase in vaccination rates, reaching over 85% for girls aged 13-18 by the end of 2020 [15][20]. - By 2022, the price for a three-dose HPV vaccine in Beijing community hospitals dropped to 1,062 yuan, averaging 354 yuan per dose, which is half the price compared to earlier years [21]. - The first domestically produced HPV vaccine, priced at 329 yuan per dose, was launched in late 2019, significantly undercutting the prices of imported vaccines [26]. Group 3: Policy and Public Health Impact - The Chinese National Health Commission announced the inclusion of the HPV vaccine in the national immunization program, prioritizing coverage for girls aged 9-14 [33]. - The drastic price reduction and increased availability of HPV vaccines are expected to address health inequalities, particularly in rural and western regions of China where cervical cancer rates are higher [25][32]. - The article emphasizes that the focus should be on widespread vaccination rather than the perfection of vaccine types, highlighting the importance of accessibility in public health initiatives [18].

Core Viewpoint - Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. plans to change the purpose of repurchased shares from "for employee stock ownership plan or equity incentives" to "for cancellation and reduction of registered capital" for 729,970 shares [2][8][10] Group 1: Share Repurchase and Cancellation - The company intends to cancel 729,970 shares, which represents 0.0577% of the current total share capital [3][9] - The total number of shares repurchased by the company as of December 21, 2022, was 1,585,320 shares, accounting for 0.1750% of the total share capital at that time [5] - As of the announcement date, 855,350 shares have been used for the 2023 employee stock ownership plan, leaving 729,970 shares unused [8] Group 2: Decision-Making Process - The board of directors and the supervisory board approved the proposal to change the purpose of the repurchased shares on October 15, 2025, and it will be submitted to the shareholders' meeting for approval [4][10][36] - The decision aims to comply with the commitments regarding the usage period of repurchased shares and to enhance investor confidence in the company's long-term value [8][10][35] Group 3: Future Plans - The company will explore other feasible incentive plans to motivate its management team and core technical personnel, aiming to support sustainable development and create value for shareholders [8][12][35]

Core Points - Wante Bio announced a change in the purpose of its repurchased shares, shifting from employee stock ownership plans to cancellation and reduction of registered capital [2] Group 1 - The company will hold its sixth board meeting and sixth supervisory board meeting on October 15, 2025 [2] - The company plans to change the usage of 729,970 shares that were repurchased but not yet utilized [2] - The new purpose for these shares will be to cancel them and reduce the registered capital [2]